DMA Diamedica Therapeutics

DiaMedica Inc., (TSX VENTURE:DMA), a biotechnology company focused on diabetes,
announced today that John M. Amatruda, M.D. has joined the company's Scientific
Advisory Board ("SAB"), enhancing DiaMedica's experienced advisory team. 


Dr. Amatruda was the former Senior Vice President and Franchise Head for
Diabetes and Obesity at Merck Research Laboratories where he lead the
development and regulatory approvals of Januvia(TM) and Janumet(TM) - the first
compounds in the DPP-IV inhibitor class for Type 2 diabetes. Prior to Dr.
Amatruda's tenure at Merck, he served as Vice President and Therapeutic Area
Research Head for the Metabolic Disorders Research at Bayer AG, as well as a
Professor of Medicine at the University of Rochester School of Medicine and an
Adjunct Professor of Medicine at Yale University School of Medicine. He is board
certified in internal medicine, endocrinology and metabolism. Dr. Amatruda is an
author on over 150 scientific papers, abstracts, reviews and book chapters. 


"We are extremely pleased to be adding a world leader in diabetes drug
development to our SAB," stated Mr. Rick Pauls, President and CEO, DiaMedica
Inc. "Dr. Amatruda's opinion is highly respected within the pharmaceutical
industry."


"It is a pleasure to join the SAB of DiaMedica," commented Dr. Amatruda.
"DiaMedica has several approaches for the treatment of diabetes and I am excited
to work with the company and its scientific advisors."


About DiaMedica 

DiaMedica is a biopharmaceutical company that has developed novel therapeutic
compounds aimed to improve the lives of patients with diabetes and other major,
medically unmet diseases. DiaMedica's lead compound, DM-199, represents a novel
approach to treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting the autoimmune
attack on beta cells; 2) proliferating insulin producing beta cells and 3)
improving glucose control.


DiaMedica is also developing DM-204, a monoclonal antibody that inhibits the
enzyme glycogen synthase kinase 3 beta (GSK3B). In preclinical studies, DM-204
significantly improved glucose control and decreased blood pressure.


The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.  

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024